Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks
Viruses · 2025
DOI: 10.3390/v17121526 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, 2025. Verfasst von Chloe Orkin und 4 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, UK. Hauptthemen laut MEDLINE: Disease Outbreaks, HIV Infections, Mpox, Monkeypox, Monkeypox virus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 115 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Bavarian Nordic.
Abstract (Originalsprache)
Human mpox, caused by the mpox virus, is a reemerging viral zoonosis that has gained global attention due to recent Clade IIb outbreaks outside of Africa, as well as ongoing Clade Ia and Ib outbreaks in the Democratic Republic of Congo (DRC) and surrounding regions. Since the start of these outbreaks in 2022, approximately 160,000 people have been affected across more than 100 countries. People with human immunodeficiency virus (HIV; hereafter referred to as PWH) have been disproportionately affected, accounting for approximately 50% of all cases. Mpox is typically a self-limiting illness causing smallpox-like symptoms lasting 2–4 weeks, which can cause significant pain and morbidity. People with uncontrolled or advanced HIV face an elevated risk of severe mpox, secondary complications, and worse outcomes. Vaccination with second- and third-generation vaccinia-based smallpox vaccines has emerged as an important tool in mpox prevention, alongside behavioural modification to mitigate risk. However, only the third-generation, live-attenuated, non-replicating vaccine, modified vaccinia Ankara (MVA-BN [Bavarian Nordic]), is approved for use in PWH. Real-world estimates suggest that two doses of MVA-BN administered as pre-exposure prophylaxis confers vaccine effectiveness in the range of 66–90%. Additionally, MVA-BN has been widely demonstrated to have an acceptable safety profile. This narrative review explores the changing epidemiology, clinical manifestations, and outcomes of mpox in PWH. We also summarise evidence from the Clade IIb outbreaks on the effectiveness and safety of MVA-BN among PWH. Despite progress in our understanding, knowledge gaps persist regarding vaccine performance in individuals with advanced immunosuppression. Furthermore, due to the emergent nature of outbreaks in the DRC and surrounding areas, limited information is available regarding implications for PWH in the context of Clade Ia and Ib. We aim to provide healthcare providers, community stakeholders, and researchers with a foundational understanding of mpox in PWH and the role of MVA-BN in mpox prevention among this group, while highlighting areas of uncertainty. These insights may be helpful in the planning of future research and to inform strategies for the prevention and management of mpox among PWH, particularly those with advanced or uncontrolled HIV.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- SHARE Collaborative, Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 4NS, UK.
- Bavarian Nordic Berna GmbH, CH-3174 Thoerishaus, Switzerland.
- Word Monster, One, St. Peter's Road, Maidenhead SL6 7QU, UK.
- UCLA School of Nursing, Los Angeles, CA 90095, USA.
- ICH Study Center, 20146 Hamburg, Germany.
- Department of Medicine II, University of Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany.
ORCID-Profile: Ian W Holloway, Christian Hoffmann
Förderung
- Bavarian Nordic
Zitieren
APA
Orkin, C., Torgler, R., Dawson, R., Holloway, I. W., & Hoffmann, C. (2025). Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks. Viruses. https://doi.org/10.3390/v17121526
Vancouver
Orkin C, Torgler R, Dawson R, Holloway IW, Hoffmann C. Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks. Viruses. 2025. doi:10.3390/v17121526
BibTeX
@article{Orkin2025,
author = {Orkin, Chloe and Torgler, Ralph and Dawson, Rebecca and Holloway, Ian W and Hoffmann, Christian},
title = {Mpox: Exploring Epidemiology, Disease Outcomes, and Preventative Vaccination Among People with HIV During the Ongoing Outbreaks},
journal = {Viruses},
year = {2025},
doi = {10.3390/v17121526}
}
EUVIMED